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INTRODUCTION 
Background: 
 Cigarette smoking continues to be one of the leading causes of preventable global mortal-
ity. Tobacco use is a significant hurdle to development gains worldwide. It is the leading cause 
of preventable death. Worldwide, only two large and growing causes of death exist. One is HIV-
1 infection, and the other is tobacco. On current consumption patterns, about 1 billion people in 
the 21stcentury will be killed by their addiction to tobacco. Smoking-related illness costs billions 
of dollars each year. 
Hazards of Smoking: 
 Tobacco is the biggest external cause of non-communicable disease and is responsible for 
even more deaths than adiposity globally. The risks in middle age are much greater for smokers 
who started in early adulthood than for those who started later. After 1950, cigarette consump-
tion continued to rise for some decades in high-income countries, and it has risen among men 
(though generally not among women) in many low- and middle-income countries. Two thirds of 
all smokers live (in descending order of numbers of smokers) in China, India, the European Un-
ion (in which central tobacco legislation can influence 28 countries), Indonesia, the United 
States, Russia, Japan, Brazil, Bangladesh, and Pakistan. In India, manufactured cigarettes are 
now displacing bidis1.  
Smoking also increases the risk of cardiovascular disease, aortic aneurysm, Cohn’s dis-
ease, gastric and duodenal ulcers, cataracts, and age-related macular degeneration. The two most 
common respiratory diseases caused by smoking are lung cancer and chronic obstructive pulmo-
nary disease (COPD). According to a study of male British doctors between 1951 and 1991, 
smoking caused 81% of lung cancer deaths and 78% of deaths from COPD. 
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Psychological Effects of Smoking 
 Psychologically, for some people, the feel, smell, and sight of a cigarette and the ritual of 
obtaining, handling, lighting, and smoking the cigarette are all associated with the pleasurable 
effects of smoking2. Nicotine induces pleasure and reduces stress and anxiety. Smokers use it to 
modulate levels of arousal and to control mood. Smoking improves concentration, reaction time, 
and performance of certain tasks. With regular smoking, the smoker comes to associate specific 
moods, situations, or environmental factors — smoking-related cues — with the rewarding ef-
fects of nicotine. Typically, these cues trigger relapse3. The legal and social barriers constantly 
test a user’s drive to smoke. A smoker is presented with nearly ubiquitous opportunities and fre-
quent cues to both purchase and use tobacco because of mass marketing and promotion of tobac-
co1. 
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Smoking Cessation: 
“Most smokers identify tobacco use as harmful and express a desire to reduce or stop using it, 
and nearly 35 million want to quit each year” 
There is substantial scientific evidence that smoking cessation helps recovery4. Quitting 
smoking has immediate and long-term health benefits. From the very first day of quitting, body 
begins to repair itself. Within days the smell and taste improves and breathing improves making 
exercise easier. Within one to nine months, coughing and shortness of breath also decrease. Peo-
ple experience nicotine withdrawal differently. Some people find it more challenging than others. 
Many people find nicotine withdrawal is worst in the first 24 - 48 hours of quitting. Symptoms of 
nicotine withdrawal includes: Irritability and anxiety, Difficulty concentrating, Restlessness and 
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insomnia, Cravings, Dizziness, Appetite changes5. Smokers are finding difficulty in managing 
these symptoms as NRTs help in reducing symptoms, but not in carvings.  
Cessation before middle age avoids more than 90 percent of the lung cancer risk attribut-
able to tobacco, with quitters possessing a pattern of survival similar to that of persons who have 
never smoked. In the United Kingdom, among those who stopped smoking, the risk of lung can-
cer fell steeply with time since cessation. 
GOVT INTERVENTIOENS TO RDUCE DEMAND FOR TOBACCO1: 
 Numerous studies, mostly from high-income countries, have examined the effect of in-
terventions aimed at reducing the demand for tobacco products on smoking and other kinds of 
tobacco use.  
• Tobacco Taxation6 
• Restrictions on Smoking 
• Health Information and Counter-advertising 
• Bans on Advertising and Promotion 
• Smoking Cessation Treatments 
• Interventions to reduce the supply of tobacco 
• Comprehensive tobacco-control Programs: 
 preventing initiation among youths and young adults  
 promoting cessation among all smokers 
 reducing exposure to passive tobacco smoke  
 identifying and eliminating disparities among population subgroup 
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THE IMPACT OF SMOKING ON THE DEVELOPMENT OF DIABETES AND ITS 
COMPLICATION 
Smoking is one of the modifiable risk factors for many chronic conditions, such as cardiovascu-
lar disease (CVD), cancer, chronic obstructive lung disease, asthma and diabetes. Smoking ces-
sation is one of the few interventions that can safely and cost-effectively be recommended for 
individuals with diabetes. In the guidelines from the American Diabetes Association, smoking 
cessation is recommended as one of the most important steps in preventingthe complications of 
diabetes.7 Many studies haveshown that the adverse effects of smoking on diabetes mellitusare 
not only related to macrovascular complicationsbut also microvascular disease.Although smok-
ing is known to decrease body weight8, itis associated with central obesity9. Substances present 
intobacco smoke undoubtedly trigger free radical processes,interfere with vascular homeostasis 
and proper functioningof the vascular endothelium,and also increase inflammation/oxidative 
stress, in addition to directly damagingβ-cell function10. A growing body of the literature has 
shown linksbetween tobacco use and the development of diabetes.11 
However, this literature is wide ranging and complex as tobacco products such as ciga-
rettes contain 7357 chemical compounds and 10 to 10free radicals, and this is in addition to the 
well-known compounds such as carbon monoxide, tar, arsenic, lead and nicotine12, leading to 
multiple pathways that may be involved in the pathogenesis. To complicate matters, each of 
these pathways is neither mutually exclusive nor linear, and there are a vast number of interac-
tions between chemicals, and interconnectivity between the inflammatory and biochemical 
pathways that they induce. Since nicotine is the critical substance which exerts most of the ad-
verse effects 
Of smoking, we will concentrate on the role of this substance in this review. The prevalence of 
smoking in youth and adults is still high and remains one of the major health problems. Many 
Previous studies documenting the impact of smoking onhealth did not discuss separately the re-
sults for subgroupsof patients with diabetes, suggesting an estimated risk of complications that is 
similar to the general population. Understanding the hazardous effects of smoking on diabetes 
Mellitus may lead to increased emphasis on smoking prevention and smoking cessation as im-
portant strategies in the management of this condition.13 
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The relationship between diabetesand smoking 
 
Diabetes is one of the most common metabolic disorders, underpinned by a combination 
of genetic, environmental and lifestyle factors. Many epidemiological studies indicatethat ciga-
rette smoking is an independent risk factorfor type 2 diabetes.The 5-year-long Insulin Resistance 
Atherosclerosis Studyconfirmed the significant effect of cigarette smoking on the development of 
diabetes in adults. In the analyzedstudy, there were nearly a thousand non-diabetic and 
Declared healthy individuals examined. The study comprised sample with 25% smoking and 
14% non-smokingpersons with diabetes. After considering the anthropometric, behavioral, meta-
bolic, gender, race and hypertension relatedfactors, it was found that the risk of type 2 diabetes 
For smokers was statistically higher than for non-smokers. 
In addition, a higher risk of diabetes was observed insmokers with normal glucose tolerance. 
There was also apositive correlation between the risk of developing type 2diabetes and smoking 
duration. Periods of intensive cigarette smoking favour the occurrence of hyperglycemia, 
Hyperinsulinaemia and hypertension.14Other work has also shown that cigarette smoking is a 
risk factor for type 2 diabetes. Men who smoke more thantwo packs of cigarettes per day have a 
45% higher risk ofdeveloping diabetes when compared to men who never smoked. In contrast, 
women who smoke over 40 cigarettesper day have a risk of developing diabetes that can be as 
much as 75% higher when compared to non-smoking women. Quitting smoking reduces the risk 
to the level observed in non-smokers within 5 years for women andmore than 10 years for 
men.15Specific studies on the effect of smoking on the risk ofdiabetes in women have been 
scarce. The results from theNurses’ Health Study in the United States (114,247 wom-
en,1,227,589 person-years follow-up) showed that the risk fordiabetes in smokers was 1.42 after 
adjustment for otherrisk factors.16 Others have found that current and pastsmoking are associated 
with a risk of diabetes mellitus essentially in men, but much less in women, and the relationship 
between fasting glucose and smoking appears differentin men and women.17 The longitudinal 
study ofJapanese males from 1984 to 1992 estimated the risk of developing type 2 diabetes was 
increased by threefold in those who smoked 16–25 cigarettes a day compared with those who 
never smoked, after controlling for other risk factors including alcohol consumption and obesi-
ty.18 Afollow-up study of this Japanese male cohort, conducted from 1994 to 1999, has estab-
lished that the level of consumption and the number of years smoked were positively correlated 
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with the development of type 2 diabetes and also to impaired fasting glucose, which often pro-
gresses to type 2 diabetes.19The study by Wannamethee et al. has demonstrated similar findings; 
the researchers studied 7124 men aged40–59 years over a period of 17 years. The cases of diabe-
tes were determined on the basis of questionnaires sent systematically by the primary care physi-
cian. Over the course of the study, 290 cases of diabetes were observed. 
After taking into account factors such as age, body mass index (BMI), and others influencing the 
onset of diabetes, cigarette smoking was statistically demonstrated to increase the risk of this 
disease. In this study, however, there was no significant relationship between the duration. 
Summary of pathways that link smoking cigarettes with diabetes pathophysiology.20 
 
Reduced insulin secretion 
The presence of neuronal nicotinic acetylcholine receptors (nAChRs) was discovered in the β 
cells of pancreatic islets. It was found that on the surface of islet cells in the pancreas, there are 
subunits of nAChRs, such as α-2, α-3, α-4, α-5, α-7 and β-2. Both in the case of acute (60 min) 
and chronic (48 h) exposure to nicotine, decreased β cell insulin secretion was observed. The 
findings suggest that nAChRs play an important role in controlling the hormone release by β 
cells. It was further found that exposure to nicotine concentrations above 1 μmol/L inhibits insu-
lin secretion in isolated human islet cells.21 
         These findings indicate that functional nicotinic receptors are present in pancreatic islets 
and β cells and nicotine could, at least in part, negatively affect pancreatic β-cell function. Thus, 
the presence of neuronal nicotinic receptors sensitive to nicotine in pancreatic cells may be ex-
plained by the mechanism of toxic influence of nicotine on insulin-secreting β cells. 
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Many animal studies have demonstrated that nicotine may affect the development of pan-
creatic cells and contribute to the development of diabetes. Several studies have shown that nico-
tine can increase apoptosis of islet β cells in nicotine exposed animal models. In an experiment 
using an animal model, the impact of prenatal and postnatal exposure to nicotine on the function 
of β cells of pancreatic islets was analyzed. The study was conducted on pregnant rats that were 
injected with a solution of hydrogen tart rate nicotine, with the control group being injectedwith 
saline. The administration of nicotine and saline continued until the end of lactation, that is, for 
21 days afterbirth. The study revealed that nicotine exposure can causeβ-cell dysfunction and 
increased β-cell apoptosis, mediated via the mitochondrial and/or death receptor pathway, which 
led to the development of impaired glucose metabolism.22Another study indicated that maternal-
ly derivednicotine can act via pancreatic nAChRs during fetal andneonatal development, leading 
to oxidative stress that inturn results in loss of pancreatic β cells. These results supportthe con-
cept that β-cell apoptosis in fetal and neonatal pancreas can be induced by a direct effect of nico-
tine vianAChRs, and that this effect may be mediated through increased oxidative stress.23  
Others found that exposure to nicotine during fetal and neonatal life stages caused an in-
crease in body fat and dysglycaemia.In experimental animal models, glucose metabolism dis-
turbances appeared at the age of 7 weeks inrates and persisted until the age of 26 weeks in rats 
exposedto nicotine during their prenatal and neonatal stages of life, with insulin resistance play-
ing a role. Therefore, smoking can induce diabetes both by increasing insulin resistance and 
through reduction of insulin secretion. Each cigarette smoked leads to an inflammatory response 
in the body and if continued, chronic pancreatitis. Prolonged smoking destroys the exocrine part 
of the pancreas (the pancreas decreases morphologically), while the pancreatic islets become re-
stricted and then destroyed.24 The studies conducted by Sarles et al. showed that smokers are 
more predisposed to pancreatic calcification than nonsmokers. This fact was also confirmed by 
Cavallini et al,who showed that for smoking patients with chronic pancreatitis, there was a 20% 
increased risk of pancreatic calcifications when compared to non-smoking patients. Further-
more,it was observed that pancreatic calcifications are formed earlier in smokers than in non-
smokers (median: 4.5 years earlier).25  
 
Studies evaluating the pancreatic exocrine function in smoking patients with chronic pan-
creatitis showed a significant impairment in the activity of the pancreatic enzymes. For many 
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years, it was thought that both parts of the pancreas – the endocrine and the exocrine –operated 
independently and had different functions in thebody. Recent studies suggest that there is an in-
teractionbetween the endo- and exocrine function of the pancreas. For example, insulin affects 
the synthesis and the secretionof enzymes by the exocrine pancreas in the acini receptor mecha-
nism. Immuno histochemical localization of insulin and glucagon in pancreatic samples differs in 
smokers and non-smokers with chronic pancreatitis, with reduced insulin detection in the former 
group, particularly in the tail of the pancreas. 
The significantly lower levels of insulin and the higherblood glucose levels in smokers 
with chronic pancreatitis in comparison to non-smokers coincided with the progressionof chang-
es in the structure and dysfunction of the endocrine organ Chemical components of tobacco 
smoke may havedirect toxic effects on the pancreas and β-cell function, both in fetal life and 
adulthood. Because higher levels of inflammatory markers [C-reactive protein and interleukin-6 
(IL-6)] herald the development of diabetes, smokingmay also contribute to the development of 
diabetes byincreasing levels of inflammatory markers.16 Furthermore, mitochondrial dysfunc-
tion, oxidative stress and inflammationare involved as underlying mechanisms for the directtox-
icity induced by nicotine via nAChRs.26-30 
Increased insulin resistance 
   In healthy people, glucose levels are maintained within the normal range through proper 
insulin secretion by β cells and the sensitivity of peripheral tissues to the action of this hormone. 
Insulin resistance, metabolic syndrome and glucose intolerance are regarded as disturbances with 
a common background and strong interrelations. Increasing insulin resistance seems to be the 
primary factor especially in the pathogenesis of type 2 diabetes, which occurs many years before 
the appearance of overt hyperglycemia. In the early stages of increased insulin resistance, the 
islet β cells ‘try’ to compensate increasing secretion of insulin. Current evidence indicates that 
smoking increases insulin resistance, although exact mechanisms remain to be elucidated      
Numerous studies have shown the negative effects of cigarette smoking on peripheral insulin ac-
tion, which appears to be ‘dose dependent’. In healthy young men, acute smoking showed an in-
creased insulin resistance. Smokers had a significantly increased homeostatic model assessment 
insulin resistance index an hour after smoking.   
The smoking reduced insulin-mediated glucose uptake by 10%–40% in men who smoked com-
pared with on-smoking men. 
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 Additionally, in healthy men, chronic smoking was associated with high plasma insulin 
concentrations, independent of other factors known to influence insulin sensitivity. This ob-
served increase in insulin resistance in smokers may be related, at least in part, to nicotine as 
long-term use of nicotine gum use is associated with hyperinsulinaemia and insulin resistance. 
The chronic smoking effect on insulin sensitivity was also evaluated in patients with type 2 dia-
betes, and the results of this study showed decreased peripheral glucose metabolism in smoking 
patients when compared to nonsmokers. Insulin and C-peptide responses to oral doses of glucose 
were significantly higher in smokers than nonsmoking patients, while the blood glucose was not 
significantly different. Thus, chronic cigarette smoking seems to increase significantly insulin 
resistance in type 2 diabetes, which may have implications for treating these patients. 
 Human experiments using the glucose-clamp technique have found that an acute infusion 
of nicotine aggravates the insulin resistance response in people with type 2 diabetes, further im-
plicating this agent in the observed changes in insulin sensitivity in smokers. On the positive 
side, the effect of smoking on insulin sensitivity may be partially reduced after quitting smoking. 
In non-obese men, insulin sensitivity improved 8 weeks after smoking cessation, despite an in-
crease in body weight.31 
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Nicotine on islet beta-cells  
Nicotine influences insulin secretion through nAChRs on beta-cells Recently, many stud-
ies have found neuronal nicotinic acetylcholine receptors (nAChRs)expressed on many different 
non-neuronal cell types includingpancreatic islet cells. Basal insulin secretion can be modulated 
by an endogenous pancreatic ganglionic mechanism. The effects of ganglion pre- and postsynap-
tic In AChRs antagonism were studied in the in vitro canine pancreas. Results suggest that nA-
ChRs are present at the ganglionic level in the pancreas and modulate insulin secretion by a 
complex intraganglionic mechanism. Direct evidence of the presence of nicotinic receptors on 
islet beta-cells has also been obtained. In that study, expression of mRNA fornAChRs subunits α 
2, α 3, α 4, α 5, α 7, and β 2 were detected in insulin secreting cells by reverse transcriptase pol-
ymerase chain reaction. Not only a long term exposure to nicotine but also acute exposure in-
duced a reduction in insulin secretion in response to insulin-secreting agonists including 
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tolbutamide. These studies suggest that nAChRs  are playing an important role in controlling in-
sulin release. Yoshikawa et al also has shown that acute exposure to nicotine at concentrations of 
higher than 1 moll/L inhibited high-glucose-induced insulin release in isolated human islets, alt-
hough these concentrations of nicotine failed to decrease the glucose-induced insulin release 
from rat islets. On the other hand, the exposure to nicotine for 48 h inhibited insulin releases 
even at basal glucose levels in rat and human islets. These findings indicate that functional nico-
tinic receptors are present in pancreatic islets and beta cells and nicotine could, at least in part, 
negatively affect pancreatic beta-cell function. Thus, the presence of neuronal nicotinic receptors 
sensitive to nicotine in pancreatic cells may be a switch to modulate pancreatic cells physiologi-
cal function by acetylcholine and can be involved in tobacco toxicity.  
 
Nicotine increases apoptosis of islet β-cells 
There are several lines of studies have shown that nicotine can increase apoptosis of islet β-cells 
in nicotine exposed animal models. In a rat model, prenatal nicotine exposure affected early 
endocrine pancreas and adipose tissue development in pups before weaning. Results proved a 
direct association between fetal nicotine exposure and offspring metabolic syndrome with early 
signs of dysregulations of adipose tissue and pancreatic development. Another two studies re-
vealed that nicotine exposure can cause β-cell dysfunction, increased β-cell apoptosis, and loss of 
β-cell mass, which is mediated via the mitochondrial and/or death receptor pathway. 
This nicotine-induced apoptosis may lead to the development of postnatal dysglycemia and obe-
sity. Recently, Bruin et al also showed that nicotine exposure caused beta-cell apoptosis and loss 
of β-cell mass. Moreover, this study indicated that maternally derived nicotine can act via pan-
creatic nAChRs during fetal and neonatal development to induce oxidative stress in the pancreas 
thus to induce loss of pancreatic β-cells. These results support that beta-cell apoptosis in the fetal 
and neonatal pancreas can be induced by a direct effect of nicotine via nAChRs and that this ef-
fect may be mediated through increased oxidative stress. All these studies in animal models have 
indicated that prenatal or neonatal exposed to nicotine will lead to loss of pancreatic β-cells, thus 
less insulin secretion. Mitochondrial dysfunction, oxidative stress, and inflammation are in-
volved as underlying mechanisms for the direct toxicity induced by nicotine. 
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THE EFFECT OF SMOKING ON INSULIN ACTION 
The exact mechanism for why smoking increases the risk of diabetes and deteriorates glucose 
homeostasis has not been fully elucidated, but the available evidence shows that smoking in-
creases insulin resistance. 
In healthy young men, acute smoking showed an increased insulin resistance . Smokers had a 
significantly increased homeostatic model assessment insulin resistance index an hour after 
smoking . The smoking reduced insulin mediated glucose uptake by 10% to 40% in men who 
smoked compared with non-smoking men . In type 2 diabetic subjects, insulin and C-peptide re-
sponses to oral glucose load were significantly higher in smokers than non-smokers and the insu-
lin resistance, as determined by the euglycemic clamp technique, was positively correlated in a 
dose dependent manner . Thus smoking induced insulin resistance in patients with type 2 diabe-
tes, as well as healthy subjects. 
In addition to increased insulin resistance, smoking also showed dyslipidemia prone to athero-
sclerosis. Smokers had higher fasting triglycerides and lower high density lipoprotein cholesterol 
levels, and an increased proportion of small dense low density lipoprotein particles. Fibrinogen 
levels and plasminogen activator inhibitor 1 activity were also elevated in smokers . 
In terms of glucose homeostasis, smoking has a negative effect on glucose control. In a popula-
tion-based prospective study, cigarette smoking was positively associated in a dose dependent 
manner with elevated HbA1c after adjustment for possible confounding by dietary variables. 
This finding was also reported in patients with diabetes in Sweden; smoking type 1 and type 2 
patients had a higher mean HbA1c but a lower mean body mass index than non-smokers.32-38 
 
SMOKING AND DIABETIC MICROVASCULAR COMPLICATIONS 
The smoking effects on micro vascular diabetes complications vary across reports. Generally, 
several studies have shown that smoking has an adverse effect on diabetic nephropathy, but the 
influence of smoking independently with glucose control, on retinopathy and neuropathy are un-
clear. 
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SMOKING AND NEPHROPATHY 
Several studies have demonstrated that smoking promotes diabetic microal buminuria and exac-
erbates diabetic nephropathy. In the study by Biesenbach et al., 39 a 13-year follow-up study, the 
progression of nephropathy was clearly increased in smokers. The authors showed that smoking 
was a risk factor for diabetic kidney disease, independent of age, sex, and duration of diabetes 
and HbA1c levels. 
In prospective studies by Chuahirun and Wesson40 and Chuahirun et al.,41 the adverse effects on 
diabetic neprhropathy in type 2 patients were confirmed, even in optimal hypertensive patients. 
SMOKING AND RETINOPATHY 
The association of smoking and diabetic retinopathy has not been clear. It was reported that reti-
nopathy has been associated with glycemic control and not smoking state. Some studies have 
reported no association with smoking and retinopathy in type 2 diabetes.42The United Kingdom 
Prospective Diabetic (UKPD) study to determine risk factors related to the incidence and pro-
gression of diabetic retinopathy followed patients over 6 years from diagnosis. The development 
of retinopathy was associated with glycemia and higher blood pressure, but not smoking. Thus in 
type 2 patients, the effects of smoking on diabetic retinopathy has not been as clear as with 
nephropathy.43 
 
SMOKING AND NEUROPATHY 
There are few studies about smoking and diabetic neuropathy. Smoking may affect diabetic neu-
ropathy differently according to the type of diabetes. In type 2 diabetic patients, smoking was not 
a risk factor in the presence of polyneuropathy or sensory neuropathy as diagnosed by symptom 
and sign. It was reported that there was no relationship between current or previous levels of 
smoking and the severity and duration of chronic painful neuropathy. But in the study by Tamer 
et al., while smoking was not associated with neuropathic complaints, using electromyography-
supported neuropathy examination there were significant relationships with smoking, as well as 
HbA1c. Therefore, more studies are needed to evaluate the association between smoking and 
neuropathy.44-47 
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SMOKING AND MACROVASCULAR COMPLICATIONS 
Smoking has been shown to be a significant risk factor for all-cause mortality, and for mortality 
due to CVD and coronary heart disease (CHD) in diabetics. Smokers die on average 8 to 10 
years younger than non-smokers, as age is entered into most multi-regression analysis. 
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DIABETES MELIITUS 
DEFINITION 
Diabetes mellitus (or diabetes) is a chronic, lifelong condition that affects your body's ability to 
use the energy found in food.  
All types of diabetes mellitus have something in common. Normally, your body breaks down the 
sugars and carbohydrates you eat into a special sugar called glucose. Glucose fuels the cells in 
your body. But the cells need insulin, a hormone, in your bloodstream in order to take in the glu-
cose and use it for energy. With diabetes mellitus, either your body doesn't make enough insulin; 
it can't use the insulin it does produce, or a combination of both. 
Since the cells can't take in the glucose, it builds up in your blood. High levels of blood glu-
cose can damage the tiny blood vessels in your kidneys, heart, eyes, or nervous system. That's 
why diabetes -- especially if left untreated -- can eventually cause heart disease, stroke, kidney 
disease, blindness, and nerve damage to nerves in the feet.48 
TYPES 
There are three major types of diabetes: type1 diabetes, type2 diabetes, and gestational diabe-
tes.49 
Type 1 Diabetes(T1DM) 
Type 1 diabetes is also called insulin-dependent diabetes. It used to be called juvenile-onset dia-
betes, because it often begins in childhood. It is an autoimmune condition. It's caused by the body 
attacking its own pancreas with antibodies. In people with type 1 diabetes, the damaged pancreas 
doesn’t make insulin. 
SYMPTOMS FOR T1DM 
 Above average thirst 
 Tiredness during the day 
 Polyuria 
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 Unexplained weight loss 
 Genital itchiness 
CAUSES FOR T1DM 
This type of diabetes may be caused by a genetic predisposition. It could also be the result of faulty 
beta cells in the pancreas that normally produce insulin. 
A number of medical risks are associated with type 1 diabetes. Many of them stem from damage to 
the tiny blood vessels in your eyes (called diabetic retinopathy), nerves (diabetic neuropathy), 
and kidneys (diabetic nephropathy). Even more serious is the increased risk of heart dis-
ease and stroke. 
DIAGNOSIS FOR T1DM 
 Ketone test 
 GAD autoantibodies test 
 C-peptide test 
TREATMENT FOR T1DM 
Treatment for type 1 diabetes involves taking insulin, which needs to be injected through 
the skin into the fatty tissue below. The methods of injecting insulin include: 
 Syringes 
 Insulin pens that use pre-filled cartridges and a fine needle 
 Jet injectors that use high pressure air to send a spray of insulin through the skin 
 Insulin pumps that dispense insulin through flexible tubing to a catheter under the skin of the 
abdomen 
A periodic test called the A1C blood test estimates glucose levels in your blood over the previous 
three months. It's used to help identify overall glucose level control and the risk of complications 
from diabetes, including organ damage. 
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Having type 1 diabetes does require significant lifestyle changes that include: 
 Frequent testing of your blood sugar levels 
 Careful meal planning 
 Daily exercise 
 Taking insulin and other medications as needed 
People with type 1 diabetes can lead long, active lives if they carefully monitor their glucose, 
make the needed lifestyle changes, and adhere to the treatment plan. 
Type 2 Diabetes (T2DM) 
Type 2 diabetes mellitus is a metabolic disorder that results in hyperglycemia (high blood glu-
cose levels) due to the body: Being ineffective at using the insulin it has produced; alsoknown as 
insulin resistance and or being unable to produce enough insulin. 
T2DM characterized by the body being unable to metabolize glucose (a simple sugar).This leads 
to high levels of blood glucose which over time may damage the organs of the body.T2DM is 
also known as non-insulin dependent or adult-onset diabetes due to its occurrence mainly in peo-
ple over 40 
Causes 
T2dm occurs when the hormone insulin is not used effectively by the cells in body. Insulin is 
needed for cells to take in glucose from the bloodstream and convert it into energy 
Ineffective use of insulin results in the body becoming resistant to insulin-also known as insulin 
resistance, which in turn causes hyperglycemia 
In advance t2dm may causes damage to insulin producing cells in the pancreas, leading to insuf-
ficient insulin production for your body's needs 
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Risk factors   
 Being overweight or obese 
 Eating an unhealthy diet  
 Physical inactivity 
 Having a first-degree relative with type 2 diabetes 
 Having high blood pressure or raised cholesterol level 
The like hood of developing T2DM is also influenced by genetics and environmental factors for 
example, research show that 
 If either parent has T2DM, the risk of inheritance of T2DM is 15% 
 If both parents have T2DM ,then the risk of inheritance is 75% 
Symptoms for T2DM 
 Excessive thirst  
 Frequent urination 
 Increased hunger 
 Extreme tiredness 
 Sudden loss of muscle mass 
Gestational Diabetes 
Diabetes that's triggered by pregnancy is called gestational diabetes (pregnancy, to some degree, 
leads to insulin resistance). It is often diagnosed in middle or late pregnancy. Because high blood 
sugar levels in a mother are circulated through the placenta to the baby, gestational diabetes must be 
controlled to protect the baby's growth and development. 
According to the National Institutes of Health, the reported rate of gestational diabetes is between 2% 
to 10% of pregnancies. Gestational diabetes usually resolves itself after pregnancy. Having gesta-
tional diabetes does, however, put mothers at risk for developing type 2 diabetes later in life. Up to 
10% of women with gestational diabetes develop type 2 diabetes. It can occur anywhere from a few 
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weeks after delivery to months or years later. With gestational diabetes, risks to the unborn baby are 
even greater than risks to the mother. Risks to the baby include abnormal weight gain before birth, 
breathing problems at birth, and higher obesity and diabetes risk later in life. Risks to the mother in-
clude needing a cesarean section due to an overly large baby, as well as damage to heart, kidney, 
nerves, and eye.50 
DIAGNOSIS OF DIABETES 
Accurate tests are available to doctors to definitively confirm a diagnosis of diabetes. Before 
tests are conducted, a diagnosis may be suspected when patients report certain symptoms. Doc-
tors will evaluate these symptoms by asking questions about the patient's medical history. 
Doctors may also carry out a physical examination, including checks for complications that 
could have already developed - examining the feet for changes in sensation, for example. 
Testing can be part of routine screening for people at risk of the disease, who may show up as 
having prediabetes. The US Department of Health and Human Services recommends diabetes 
testing for anyone overweight at the age of 45 years and over, alongside anyone under the age of 
45 with one or more of the following risk factors: 
 Hypertension (high blood pressure) 
 High cholesterol 
 History of diabetes in the family 
 African-American, Asian-American, Latino/Hispanic-American, Native American or Pacific 
Islander background 
 History of gestational diabetes (diabetes during pregnancy) or delivering a baby over 9 lbs. 
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Blood tests for diabetes diagnosis 
Diagnoses of diabetes are confirmed through 1 of 3 types of blood test. 
One of three blood tests can be used to confirm a diagnosis of diabetes, 
 Fasting plasma glucose (FPG) levels - a blood test after 8 hours of no eating 
 Glycosylated  hemoglobin (HbA1c) - to measure a marker of the average blood glucose level 
over the past 2-3 months 
 Oral glucose tolerance testing (OGTT) - a test used less frequently that measures levels before 
and 2 hours after consuming a sweet drink (concentrated glucose solution). 
Glycosylated hemoglobin is often abbreviated to A1C, and this blood test is also used in the 
monitoring of diabetes management 
To make an initial diagnosis, an HbA1c reading must be 6.5% or higher. An A1C result between 
5.7% and 6.4% indicates prediabetes and a risk of type 2 diabetes. 
The HbA1c is the preferred blood test for diagnosis because - while it is more expensive than the 
FPG test - it has advantages, including, 
Urine tests for diabetes were once common but are no longer considered reliable. 
 Greater convenience (no need for fasting) 
 Less day-to-day variation during stress and illness. 
When the fasting plasma glucose test is used to confirm symptoms, diabetes is diagnosed at lev-
els equal to or above 126 mg/dL(7.0 mmol/L). 
For oral glucose tolerance testing, the plasma glucose levels after 2 hours need to be equal to or 
above 200 mg/dL (11.1 mmol/L) for a diabetes diagnosis. 
Another blood test is the random plasma glucose test - taken regardless of time and eating - 
which diagnoses diabetes if the level is at least 200 mg/dL (11.1 mmol/L). 
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Unless the clinical picture is clear, a positive blood test should also be repeated to rule out labor-
atory error. 
Urine tests for diabetes diagnosis 
Urine tests are no longer used to make a diagnosis of diabetes, although they were once common. 
Blood tests are used instead because urine tests are not sensitive or specific enough and offer on-
ly a crude indication of high blood sugar levels. 
A urine sample may be used, however, to test for ketones,  particularly in people with type 1 dia-
betes who exhibit certain symptoms. Here, the test can pick up ketoacidosis, a complication of 
diabetes. 
Treatments for Diabetes 
Type 2 diabetes has a number of drug treatment options to be taken by mouth known as oral an-
tihyperglycemic drugs or oral hypoglycemic drugs. 
Oral diabetes drugs are usually reserved for use only after lifestyle measures have been unsuc-
cessful in lowering glucose levels to the target of an HbA1c below 7.0%, achieved through an 
average glucose reading of around 8.3-8.9 mmol/L (around 150-160 mg/dL). 
The lifestyle measures that are critical to type 2 diabetes management are diet and exercise, and 
these remain an important part of treatment when pills are added. 
People with type 1 diabetes cannot use oral pills for treatment, and must instead take insulin 
 
is the most widely used oral antihyperglycemic drug and reduces the amount of glucose released 
by the liver into the bloodstream. 
Oral antihyperglycemic drugs have three modes of action to reduce blood glucose levels: 
 Secretagogues enhance insulin secretion by the pancreas 
 Sensitizers increase the sensitivity of the peripheral tissues to insulin 
 Inhibitors impair gastrointestinal absorption of glucose. 
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Each class of antihyperglycemic drug has a different adverse event or safety profile, and side ef-
fects are the main consideration when it comes to choosing a medication. 
Possible side effects range from weight gain, through gastrointestinal ones such as diarrhea, to 
pancreatitis and more serious problems. Hypoglycemia is also a possible adverse event. 
Biguanides 
Metforminis usually the first treatment offered, however, and it is the most widely used oral an-
tihyperglycemic. Metformin is a sensitizer in the class known as biguanides; it works by reduc-
ing the amount of glucose released by the liver into the bloodstream and increasing cellular re-
sponse to insulin. A metformin pill is usually taken twice a day 
This drug is a low-cost antihyperglycemic with mild side effects that can include diarrhea and 
abdominal cramping. Metformin is not associated with weight gain or hypoglycemia. 
 
Sulphonylureas  
Which are secretagogues that increase pancreatic insulin secretion. There are several drug names 
in this class, including: 
 Chlorpropamide 
 Glimepiride 
 Glipizide 
 Glyburide. 
Again, the choice of drug is an individual one. In the case of sulphonylureas, the choice depends 
on daily dosing and the level of side effects. These drugs are associated with weight gain and hy-
poglycemia. 
Glitazones (also known as thiazolidinediones) 
Glitazones  are sensitizers - they increase the effect of insulin in the muscle and fat and reduce 
glucose production by the liver. 
Two glitazones are available: pioglitazone and rosiglitazone. These drugs can have the side ef-
fects of weight gain or swelling and are associated with increased risks of heart disease and 
stroke, bladder cancer and fractures. 
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In the UK, rosiglitazone was withdrawn from the market over concerns about adverse events. In 
2015, it remains available in the US, with information on its safety provided by the US Food and 
Drug Administration (FDA). 
 
Alpha-glucosidase inhibitors 
They  are intestinal enzyme inhibitors that block the breakdown of carbohydrates into glucose, 
reducing the amount absorbed in the gut. 
Available as Acarbose and Miglitol, they are not usually tried as first-line drugs because of 
common side effects of flatulence, diarrhea and bloating, although these may reduce over 
time.Dipeptidyl peptidase-4 (DPP4) inhibitors  
DPP4 includesAlogliptin, Linagliptin, Saxagliptin and Sitagliptin. 
Also known as gliptins, DPP4 inhibitors have a number of effects, including stimulating pancre-
atic insulin (by preventing the breakdown of the hormone GLP-1). They may also help with 
weight loss through an effect on appetite. 
These drugs do not increase the risk of hypoglycemia. Mild possible side effects are nausea and 
vomiting. 
Sodium-glucose co-transporter 2 (SGLT2) inhibitors 
SGLT2 includeCanagliflozin and Dapagliflozin. They work by inhibiting the reabsorption of 
glucose in the kidneys, causing glucose to be excreted in the urine (glycosuria). 
SGLT2s may also cause modest weight loss. Side effects include urinary infection. 
Meglitinides  
These include Repaglinide and Nateglinide. They stimulate the release of insulin by the pancre-
as. Meglitinides are associated with a higher chance of hypoglycemia and must be taken with 
meals three times a day. As a result, these drugs are less commonly used.51 
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AIM&OBJECTIVES 
Aim: 
 To identify role of clinical pharmacist in reducing smoking frequency and physiological 
assessment in diabetic patient by using physiological assessment scale 
Objectives: 
 The main objectives of the study is, 
 To assess the physiology of smokers in DIABETIC patients by using physiological 
assessment scale  
 To counsel the diabetic patient about the harmful effect of smoking 
 To reduce the frequency of smoking in diabetic patients 
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REVIEW OF LITERATURE 
A literature review is a summary of previous research on a topic. My literature review focused 
on the smoking frequency and physiological assessment in diabetic patient 
 Mariola Śliwińska-Mossoń, et.al., .conducted a study on The impact of smoking on the 
development of diabetes and its complications. In this review they summarized that the 
Diabetes is one of the most common metabolic disorders and emerges secondary to an 
interaction between genetic, environmental and lifestyle factors. This work provides an 
overview of the impact of smoking on the development of vascular complications in this 
condition and also provides an overview of the potential role of smoking in predisposition to 
diabetes. There are many studies documenting the impact of smoking on health (not focused 
on patients with diabetes), suggesting that the health exposure in these individuals is at least 
comparable to that observed in the general population. Distinct studies of smoking in patients 
with diabetes have unambiguously confirmed an increased prevalence and a higher risk of 
early death associated with the development of macrovascular complications. Smoking is 
also associated with premature development of microvascular complications and may 
contribute to the pathogenesis of type 2 diabetes. It has been shown that smoking is a 
predictor of the progression of glucose intolerance at both the transition from 
normoglycaemia to impaired glucose tolerance status and the increased risk of developing 
diabetes. The mechanisms explaining the relationship between smoking and the development 
of diabetes are not fully understood, although a number of hypotheses have been put forward. 
Current evidence indicates that smoking cessation is not only important to prevent 
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macrovascular complications in diabetes, but also has a role in limiting microvascular disease 
and may also facilitate glycemic management in this condition.52 
 JoAnn Eet.al.,studied a review article namely a prospective study of cigarette smoking and 
the incidence of diabetes mellitus among us male physicians. This review aims to determine 
the association between cigarette smoking and the incidence of type 2 diabetes mellitus. They 
concluded that Smokers had a dose-dependent increased risk of developing type 2 diabetes 
mellitus: compared with never smokers,in these prospective data from the Physicians’ Health 
Study support the hypothesis that cigarette smoking is an independent and modifiable 
determinant of type 2 diabetes mellitus. The biologic plausibility of this association lends 
further credence to a causal interpretation, and the found that type 2 diabetes can be added to 
the list of major adverse health outcomes linked to smoking. Strategies to prevent the 
adoption of cigarette smoking or to facilitate smoking cessation may also reduce the 
incidence of diabetes and its complications. Populations at high risk of type 2 diabetes 
mellitus should be considered for special targeted smoking interventions. Guidelines for 
physicians (27) to ask about tobacco use and to assist smokers to quit could help reduce the 
burden of diabetes as well as the even larger burdens of cardiovascular disease and cancer.53 
 Carole Willi, MD, et.al.,studied the association between active smoking and the incidence 
of type 2 diabetes. In this observational study they reported risk of impaired fasting glucose, 
impaired glucose tolerance, or type 2 diabetes in relationship to smoking status at baseline; 
had a cohort design; and excluded persons with diabetes at baseline. Here concluded that 
active smoking is associated with an increased risk of type 2 diabetes.54 
 Navidad Canga, Bsc, et.al., studied a review article namely Intervention Study for Smoking 
Cessation in Diabetic Patients. This review aims to evaluate the effectiveness of a nurse-
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managed smoking cessation intervention in diabetic patients.They concluded thata structured 
intervention managed by a single nurse was shown to be effective in changing the smoking 
behavior of diabetic patients. The higher effectiveness of our intervention could be explained 
not only by the longer time spent with each patient but also because the intervention followed 
the guidelines of the Agency for Health Care Policy and Research, which include face-to-
face counseling, behavioral therapy techniques, NRT, and relapse prevention The 
participants in this study were probably particularly resistant to change. They had been 
diagnosed with diabetes several years before, and they had received health professionals’ 
advice to quit smoking repetitively. Therefore, many previous interventions by health 
professionals had failed.55 
 S. GOYA WANNAMETHEE;PHD,et.al., concluded  a prospective study on Smoking as a 
Modifiable Risk Factor for Type 2 Diabetes in Middle-Aged Men. The study aimed to 
examine the effects of cigarette smoking, giving up smoking, and primary or secondary pipe 
or cigar smoking on the risk of type 2 diabetes. The study that concluded that Cigarette 
smoking is an independent and modifiable risk factor for type 2 diabetes. Smoking cessation 
is associated with weight gain and a subsequent increase in risk of diabetes, but in the long 
term, the benefits of giving up smoking outweigh the adverse effects of early weight gain.56 
 Nwaokoro Joakin Chidozieet.al., conducted a study on the effect of smoking on Type 2 
Diabetic Patients in Federal Medical Center Owerri, in Southeastern Nigeria.the study 
concluded that the comprehensive programs should be initiated to prevent smoking in type 2 
diabetic patients such as: regular physical activity, health education on diabetes, smoking 
cessation, home blood sugar monitoring - minimize smoking impact to body organs that may 
lead to many complications. Only a low proportion of Type 2 diabetic patients were smokers 
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due to lack of proper awareness and education on the effect of smoking on diabetes, the 
disease is spreading widely and silently in Nigeria and other countries in world. More than 
half of the patients found that smoking did not give improvement rather than worsens their 
Type 2 diabetes. People with diabetes already have an increased risk of developing diabetic 
related complications and this will further elevate if they smoke.57 
 Carole Clair, MD MSc, et. al., conducted a cohort, cross-sectional and case–control studies 
on The Effect of Cigarette Smoking on Diabetic Peripheral Neuropathy: A Systematic 
Review and Meta-Analysis. This review aims to study was to assess the relationship between 
smoking and DPN in persons with type 1 or type 2 diabetes. They concluded that the 
smoking may be associated with an increased risk of developing DPN. This is an important 
finding, as this exposure is a modifiable behavior to be targeted in clinical practice based on 
diabetes guideline recommendations. Future research should be focused on evaluating the 
impact of smoking cessation on improvement of diabetic neuropathy, and on helping to 
establish a causal link between exposure and outcome.58 
 Xi-tao XIEet.al., conducteda study on nicotine effects on insulin action and insulin 
secretion, indicating the impact of nicotine on type 2 diabetes development. The study 
concluded that nicotine exposure could induce a reduction of insulin release, and negatively 
affect insulin action, suggesting nicotine could be a cause for development of insulin 
resistance. Mitochondrial dysfunction, oxidative stress, and inflammation are involved as 
underlying mechanisms of nicotine induced pancreatic β-cells loss. These evidences together 
indicate that cigarette smoking can affect insulin action and pancreatic cell function. To 
facilitate the development of diabetes, besides the well-known risk for cardiovascular and 
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other disease. Thus, in diabetes care, smoking cessation is important for glycemic control and 
limiting the development of diabetic complications.59 
 Maija Feodorof, et.al., conducted that a study on Smoking and progression of diabetic 
nephropathy in patients with type 1 diabetes. The purpose of the study contains to evaluate 
the effect of cumulative smoking on the development of diabetic nephropathy. Study 
included 3613 patients with type 1 diabetes, participating in the Finnish Diabetic 
Nephropathy Study. The 12-year cumulative risk of microalbuminuria, macroalbuminuria 
and end-stage renal disease (ESRD) was estimated for current, ex- and nonsmokers. Cox 
regression analyses, with multivariable adjustments for other risk factors for diabetic 
nephropathy, were used to evaluate the risk at different stages of diabetic nephropathy based 
on the cumulative amount of smoking in pack-years. In the current smokers, one pack-year 
increased the risk of macroalbuminuria with a HR of 1.025 (1.010–1.041) and the risk of 
ESRD with a HR of 1.014 (1.001–1.026) compared with nonsmokers, in the fully adjusted 
model. In the ex-smokers, the risk of macroalbuminuria and ESRD was no different from the 
risk in nonsmokers after multivariable adjustment. The study concluded that Current smoking 
is a risk factor for the progression of diabetic nephropathy and the risk increases with the 
increasing dose of smoking. Ex-smokers seem to carry a similar risk of progression of 
diabetic nephropathy as nonsmokers.60 
 Eric B Rimm, et.al., this prospective study concluded that the Cigarette smoking may be an 
independent, modifiable risk factor for non-insulin dependent diabetes mellitus. Moderate 
alcohol consumption among healthy people may be associated with increased insulin 
sensitivity and reduced risk of diabetes. After controlling for known predictors of diabetes we 
found positive association between smoking and the subsequent risk of diabetes. This study 
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included an increased risk among current and former smokers, supporting experimental 
evidence that smoking exerts both short term effect on insulin sensitivity and long term effect 
on insulin secretion. The study confirm results in women for both alcohol consumption and 
smoking and support laboratory evidence that, compared with men who abstain, men who 
take up to three drinks day are more insulin sensitive and may be at lower risk of diabetes. 
These findings from large prospective cohort of men suggest that factors in addition to 
obesity can modify the incidence of diabetes.61 
 Julie C Wil, et.al., conducted a study on Cigarette smoking and diabetes mellitus: evidence 
of a positive association from a large prospective cohort study.The purpose of this study was 
to determine whether greater frequency of cigarette smoking accelerated the development of 
diabetes mellitus, and whether quitting reversed the effect. The study concluded that a dose-
response relationship seems likely between smoking and incidence of diabetes. Smokers who 
quit may derive substantial benefit from doing so. Confirmation of these observations is 
needed through additional epidemiological and biological research.62 
 Jiang N, et.al., conducted a study on Smoking and the risk of diabetic nephropathy in 
patients with type 1 and type 2 diabetes: a meta-analysis of observational studies. The 
observational study aimed to assess the effects of tobacco smoking on the development of 
M.Th.study concluded that A total of nineteen observational studies (1 case-control, 8 cross-
sectional and 10 prospective cohort studies) were identified, involving more than 78,000 
participants and a total of 17,832 DN cases. Compared with never-smokers, there was an 
augmented SRR (95% CI) of DN in ever-smokers in patients with T1DM (1.31 [1.06-1.62]; 
P = 0.006) and T2DM (1.44 [1.24-1.67]; P < 0.001), respectively. In patients with T1DM, the 
SRR (95% CI) was 1.25 (0.86-1.83) for microalbuminuria only, 1.27 (1.10-1.48) for 
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macroalbuminuria only, and 1.06 (0.97-1.15) for end-stage renal disease (ESRD) .The  meta-
analysis suggests evidence for cigarette smoking as an independent risk factor for the 
development of DN in patients with both T1DM and T2DM.63 
 GIOVANNI TARGHER, et.al., concluded a study on Cigarette Smoking and Insulin 
Resistance in Patients with Noninsulin-Dependent Diabetes Mellitus. This cross-sectional 
study shows that chronic cigarette smoking can exert a deleterious impact on insulin 
sensitivity in patients with NIDDM and may bring a more complete expression of the insulin 
resistance syndrome. Because insulin resistance has been involved, by direct or indirect 
mechanisms, in the pathogenesis of hyperglycemia and macroangiopathy, smoking cessation 
in NIDDM patients might favorably affect not only cardiovascular risk, but also long-term 
metabolic control. The study compared NIDDM subjects who stopped smoking or continued 
to smoke, are needed to substantiate this hypothesis, especially because smoking cessation 
often results in weight gain, and this might adversely affect insulin sensitivity. It concluded 
that the smoking status should be carefully considered in case-control studies, including 
subjects with NIDDM.64 
 Ying Wang, et.al., conducted a study on Passive Smoking and Risk of Type 2 Diabetes: A 
MetaAnalysis of Prospective Cohort Studies. This review aims to explore whether an 
association exists between passive smoking and risk of type 2 diabetes. In conclusion found 
that the present meta-analysis suggests that passive smoking is associated with an increased 
risk of T2DM. However, considering the limited number and moderate quality of included 
studies, further well-designed studies are warranted to confirm this observed association.65 
 Toshimi Sairenchi, et.al., conducted a prospective study on Cigarette Smoking and Risk of 
Type 2 Diabetes Mellitus among Middle-aged and Elderly Japanese Men and Women in 
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japan.the purpose of the study included that for  examination of sex- and age-specific 
relations between smoking and risk of type 2 diabetes mellitus. Then the study showed that 
current smoking was associated with a 20–40 percent increased risk of diabetes mellitus, of 
which 99 percent was type 2 diabetes (13), among men and a 40–50 percent increased risk 
for both age subgroups (40–59 years and 60–79 years) among women and concluded that 
cigarette smoking was associated with increased risk of type 2 diabetes mellitus among both 
middle-aged and elderly men and women.66 
 D Haire-Joshu,et.al., conducted a study on smoking and diabetes. The objective of this 
review is to summarize the literature on diabetes and smoking related to epidemiological 
risks, efficacy and cost-effectiveness of different cessation approaches, and implications for 
clinical practice. This study concluded thatthere is a clear need to increase the frequency of 
smoking cessation advice and counselling for patients with diabetes given the strong and 
consistent data on smoking prevalence; combined risks of smoking and diabetes for 
morbidity, mortality, and several complications; and the proven efficacy and cost-
effectiveness of cessation strategies.67 
 Deborah j. Toobert, PhD, et.al., reviewed a study on The Summary of Diabetes Self-Care 
Activities Measure, Results from 7 studies and a revised scale. The study was done to review 
reliability, validity, and normative data from 7 different studies, involving a total of 1,988 
people with diabetes, and provide a revised version of the Summary of Diabetes Self-Care 
Activities (SDSCA) measure. in this study was found that the Participants were typically 
older patients, having type 2 diabetes for a number of years, with a slight preponderance of 
women. The average inter-item correlations within scales were high (mean = 0.47), with the 
exception of specific diet; test-retest correlations were moderate (mean = 0.40). Correlations 
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with other measures of diet and exercise generally supported the validity of the SDSCA 
subscales (mean = 0.23).the reviewed study was concluded that The SDSCA questionnaire is 
a brief yet reliable and valid self-report measure of diabetes self-management that is useful 
both for research and practice. The revised version and its scoring are presented, and the 
inclusion of this measure in studies of diabetes self-management is recommended when 
appropriate.68 
 Saito K, et.al., conducted a study on Effect of smoking on diabetes mellitus and 
dyslipidaemia (effect of smoking on glucose and lipid metabolism).in this study was found 
that Smoking is one of the important risk factors of cardiovascular disease. Its effects on 
arteriosclerotic diseases act not only directly but indirectly, by worsening control of blood 
pressure, lipid metabolism and glucose metabolism. And in patients with diabetes, it affects 
both macroangiopathy and diabetic microangiopathy (especially diabetic nephropathy) 
adversely. This study was concluded that the all effects and mechanisms of smoking on 
metabolic diseases are not yet unclear. But smoking cessation improves lipid metabolism and 
may improve glucose metabolism and may decrease risk of impaired glucose tolerance, type 
2 diabetes, and diabetic microangiopathy. All patients with metabolic diseases must quit 
smoking for control of diseases and prevention of arteriosclerotic disease as soon as 
possible.69 
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PLAN OF WORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collection of Various Articles Related With Diabetes And Smoking  
Designing of Proforma 
 
     Patient selection  ( diabetic patient with smoking) 150 Nos 
Inclusion Criteria. 
Type 1 & type 2 diabetic 
patient with smoking 
Exclusion Criteria. 
Women’s ,age below 18, 
psychotic patients are 
excluded 
Diabetic profile of each patients collected, 
Laboratory findings of each patient 
including BMI, insulin therappy 
Assessment of Each Patient 
Modified Fagerstorm 
psychological assessment scale 
Role of pharmacist in smoking cessation, 
decreasing smoking frequency 
 
Pictorial, videos, pamphlets & 
Effective patient counseling 
 
 Regular Follow up of 150 Patients. 
         Six month follow up, July 2017 
to December 2017 
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METHODOLOGY 
Study Period: 
 This study is carried out for a period of six months (July 2017 to December 2017). 
Study Design: 
It is a prospective study and carried out in patients arriving in Tirupur Govt. Hospital.     
Sample Size:  
 A total of 150 patients with diabetic and smoking from the general medicine ward of 
Government Headquarters Hospital, Tiruppur were included in the study 
Study Method: 
 The Study is to be conducted in Govt. Headquaters Hospital, Tirupur- 18. 
 The study method involves selection of patients based on the inclusion criteria. 
 The data collected will be analyzed using suitable statistical tools. 
Inclusion Criteria: 
 Smokers of any age, who are affected by Diabetes 
 Type 1 and Type 2 diabetes patients registered in the hospital 
 Patients with co-morbiditie 
Exclusion Criteria: 
 Patient who are not willing to participate. 
 Psychiatric patients. 
 Ladies. 
 Age below 18 yrs. 
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Design of patient consent form: 
 The consent from the patient was obtained before inclusion to the study. The consent was 
prepared in English as well as in local language.  
Data collection: 
The data collection will be done during the interview with patients at an interval of once 
in every two months in order to understand patient details including past medical history, past 
medication history, social history, marital status, occupation, family history, Diabetic profile   , 
history of present illness etc. Laboratory investigation and other relevant details of related to the 
study will be included.  
Diagnosis/questionnaire: 
A complete smoking history is a prerequisite for providing support and motivation in 
smoking cessation for DIABETIC patients. This history results in a higher number of patients 
who successfully cease smoking, but it is currently not taken often enough. Tobacco 
consumption should therefore be assessed and documented regularly (level of recommendation 
⇑⇑, that is: strongly recommended). 
To determine the extent of dependence, the Modified Fagerstrom psychological 
assessment scale is particularly suitable of 6questions, the 2 main ones are: 
 How soon after you wake up do you smoke your first cigarette? 
 How many cigarettes do you smoke each day? 
Modified Fagerstrom psychological assessment scale: 
1.  How many cigarettes a day do you smoke?  
     a. Over 26 cigarettes a day (2)  
     b. About 16-25 cigarettes a day (1)  
    c. About 1-15 cigarettes a day (0)  
    d. Less than 1 a day (0)  
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2.  Do you inhale?  
    a. Always (2)  
    b. Quite often (1)  
    c. Seldom (1)  
    d. Never (0)  
3  How soon after you wake up do you smoke your first cigarette?  
    a. Within the first 30 minutes (1)  
    b. More than 30 minutes after waking but before noon (0)  
    c. In the afternoon (0)  
    d. In the evening (0)  
4. Which cigarette would you hate to give up?  
    a. First cigarette in the morning (1)  
    b. Any other cigarette before noon (0)  
    c. Any other cigarette afternoon (0)  
    d. Any other cigarette  
     in the evening (0)  
5. Do you find it difficult to refrain  
    from smoking in places where it is forbidden (church, library, movies,  
    etc.)?  
    a. Yes, very difficult (1)  
    b. Yes, somewhat difficult (1)  
    c. No, not usually difficult (0)  
    d. No, not at all difficult (0)  
 6. Do you smoke if you are so ill that you are in bed most of the day?  
     a. Yes, always (1)  
     b. Yes, quite often (1)  
     c. No, not usually (0)  
     d. No, never (0)  
7. Do you smoke more during the first 2 hours than during the rest of the day?  
     a. Yes (1)  
     b. No (1)  
RESULTS 
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RESULTS 
 
Age Wise Classification: 
Table:1 
Age 
No Of 
Patients 
Percentage 
30 -39 9 6 
40 -49 46 31 
50 -59 40 27 
60 -69 36 24 
70 -79 19 12 
 
 
 
Dialy Cigarettes : 
Table:2 
No of 
Cigarettes 
No Of 
Patients 
Percentage 
≥20 82 55 
≤20 68 45 
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Figure:1 
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Education Level : 
Table:3 
Education No Of 
Patients 
Percentage 
Primary 
Education 
104 69 
High 
School 
31 21 
College 
Degree 
16 10 
 
 
Smoking Years: 
Table:4 
Year No Of 
Patients 
Percentage 
1 to 10 11 7 
11 to 20 45 30 
21 to 30 47 31 
31 to 40 47 32 
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Diabetic Complication: 
Table:5 
Complication No Of 
Patients 
Percentage 
Neuropathy 26 17 
Nephropathy 11 7 
Retinopathy 9 6 
Foot Ulcer 5 4 
 
 
 
Insulin Therapy: 
Table:6 
Insulin No Of 
Patients 
Percentage 
Yes 35 23 
No 115 77 
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Oral Hypo Glyciemic Agents: 
Table:7 
OHGs No Of 
Patients 
Percentage 
Yes 149 99 
No 1 1 
 
 
 
Type Of DM: 
Table:8 
Type No Of 
Patients 
Percentage 
Type 1 28 18 
Type 2 122 82 
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Diabetic Duration: 
Table:9 
Duration No Of 
Patients 
Percentage 
Below 3 11 8 
3 to 10 14 70 
Above 
10 
35 22 
 
: 
Table:10 
Range No Of 
Patients 
Percentage 
< 23 37 25 
23 - 24.4 39 26 
24.4 - 
26.4 
38 25 
≥26.4 36 24 
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           FS Scale Score: 
               Table:11 
Before After 
5 3 
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FBS: 
Table:12 
          FBS DECREASED        FBS NEUTRAL     FBS INCREASED 
Before After Before After Before After 
162 137 124 124 125 138 
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RBS: 
Table:13 
RBS DECREASED RBS NEUTRAL RBS INCREASED 
Before After Before After Before After 
205 173 169 169 174 189 
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PPBS: 
Table:14 
PPBS DECREASED PPBS NEUTRAL PPBS INCREASED 
Before After Before After Before After 
220 195 170 170 190 204 
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HbA1c: 
Table:15 
HbA1C DECREASED HbA1C NEUTRAL HbA1C INCREASED 
Before After Before After Before After 
220 195 170 170 190 204 
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Discussion 
 Table 1 & Figure 1shows that age group from 40 to 49 are more prone to be affected by 
Diabetes with the percentage of 31 among smokers followed by 50-59, 60-69, 30-39 & 
70-79 with the corresponding percentage of 27, 24, 6 & 12 respectively. The author states 
that the incidence of Diabetes Mellitus is increasing above 40 yrs of age groups. 
 Table 2 & Figure 2 indicate that 55% of the patient population were Heavy smokers with 
≥20 cigarettes per day. 
 Table 3 & Figure 3 denote that 69% of the patient population were found to be  with only 
the Primary education and remaining patients are having high school , college degree 
Education with the percentage of 21 and 10 respectievly . 
 Table 4 & Figure 4 signify that  32%, 31% and 30% & 7% of patients were 31-40 , 21-
30, 11-20 & 1-10 respectively. 
 Table 5 & Figure 5 represents that Neuropathy were found to be more predominant in 
Diabetic patients rather than other complications of Nephropathy, Retinopathy & Foot 
Ulcer on among Diabetic smokers with the percentages of 17, 7, 6& 4 respectively 
 Table 6 & Figure 6 signifies that ,  A minimum of  patients were treated with Insulin .A 
less number of patients of 35 with the percentage of 23  . 
 Table 7& Figure 7 shows that Oral Hypo Glyciemic agents   were prescribed for most of 
the patient with 99% of  prescription. the oral Hypo Glyciemic agents were found to be 
the most comfortable treatment for the diabetes followed by the insulin in some kind of 
patients . 
 Table 8 & Figure 8 shows that type2 diabetes were mostly founded in all over the   
diabetic patients which here studied .Here the numbers of  type 2 diabetic patient were 
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found to be 122 from all among 150 diabetic patients with the percentage of 81 and type 
1 diabetes is just 22% 
 Table 9 & Figure 9 Indicates that the diabetic duration were found highly in 3-10 years 
.Here  104 patients were in 3-10 years under diabetes ,Other patients were under diabetes 
either  above 10 years or below 3 years with the percentage of 22 & 8 respectively  
 Table 10 & Figure 10 shows the Body Mass Index of diabetic patients .Were the body 
mass index are found 25%, 26%, 25%, & 24% at the range of <23, 23-24.4, 24.4-26.4, 
≥26.4 are respectively. 
 Table 11 & Figure 11 Indicates that the overall Modified Fagerstrom Psychological 
assessment score were reduced  as the effect of various counseling aids & methods and 
regular follow up of DIABETIC patients, by which the table proves that counseling plays 
an important role in reducing the smoking frequency among DIABETIC patients. The 
author stated that smoking cessation ranks among the most effective medical 
interventions. Hence through appropriate counseling aids and with the help of a 
pharmacist, the patient can find it little bit easier at least in reducing the number of 
cigarette smoking and thereby, it may help the DIABETIC patients in reducing or 
managing the severity of the disease. 
  The individual scores of individual questions from Modified Fagerstrom Psychological 
assessment scale were reduced. Thereby indicating that there is a specific role for a 
pharmacist in patient care especially in reducing smoking among DIABETICpatients. 
 Table 12 & Figure 12 shows that the Fasting Blood Sugar (FBS) were decreased after the 
counseling and follow up of each patients indicates the positive results in such patients. 
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The average of FBS founded for the decreased number of patients were turn 162 to 137 
only for the limited patients. 
 Table 13 & Figure 13 shows the Random Blood Sugar level were Increased, neutral, 
decreased for different group of patients and the averages of increased and decreased 
were found to be 174-189 and 205-173 respectively. It gives a positive results in such 
contemplator patients. 
 Table 14 & Figure 14 Indicates the Post Prandial Blood Sugar(PPBS) level were 
Increased,  Decreased on  different group of patients and the averages of increased and 
decreased were found to be 190-204, 220-195.These indicates a positive results in 
counseling. 
 The Table 15& Figure 15 shows the decreasing , increasing and neutral levels of 
laboratory results as HbA1C (glycated protein) . Were the decreased and increased levels 
are 12.2-11.7, 10.8-11 respectively. It indicates the positive result in counseling the 
patients and proves that counseling plays an important role in patient care.  
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CONCLUSION 
 
 The present study shows that the modified Fagerstrom scale questionnaire scores were 
decreased after the appropriate counseling aids given to the patients than the first 
observation. Hence a clinical pharmacist can not only save the patients but also serve the 
public in smoking cessation and also to avoid the consequent effect of second hand 
smoking. 
 Our study suggest that a structured intervention properly conducted by the pharmacist can 
achieve a significant increase in smoking cessation incidence among diabetic patients. 
 Also the study signifies that reducing in the numbers of smoking frequency will 
definitely help the patient to manage their further complications of the disease. 
 This study shows that the role of clinical pharmacist is vital in reducing smoking 
frequency in which many patients fails to do by their own, even though they are ready to 
quit. And the psychological assessment in DIABETIC patients made a positive result in 
reducing smoking frequency. 
 The study shows that the laboratory values such as FBS, RBS, PPBS & HbA1c are 
decreased in some patients. It Indicated that this counselling reduced the  diabetic risk  by 
reducing the smoking frequency. 
 Also, by means of these results our study shows that the contemplation of patient or 
participation of patients in counseling programs as  contemplation can make a positive 
change in decease condition     
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DRAWBACKS 
 
 The study Population is low; hence it is difficult to attain a statistical significant result 
since the chances of error were more. 
 Also the study period was less to draw a definite conclusion for the study. Hence other 
pathological, physiological and life style strategies may markedly interfere with the study 
results.  
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PATIENT PROFORMA 
 
Name :                                                   Age:                  Gender: 
IP NO:                        DOA:        DOD:                Ward: 
Address :                          Mob No:     
 
Reason for admission : 
Past medical history : 
 
Smoker: Y/N      year:            Alcoholic: Y/N                    BMI: 
Marital status :                         Financial status:                 Occupation :    
Co morbidities :       
Diabetic profile: 
Type of diabetes: 
Diabetic complication if any: 
Use of insulin: 
Profile Initial 2nd follow up 3rd follow up 
FBS    
RBS    
PPBS    
HbA1C    
 
Psychological Assessment score: 
Before counseling After counseling 
  
 
 
  
 
Modified Version of the Fagerstrom Tolerance Questionnaire (mFTQ)  
 
 
 
1. How many cigarettes a day do you smoke?  
a. Over 26 cigarettes a day (2)  
b. About 16-25 cigarettes a day (1)  
c. About 1-15 cigarettes a day (0)  
d. Less than 1 a day (0)  
 
2. Do you inhale?  
a. Always (2)  
b. Quite often (1)  
c. Seldom (1)  
d. Never (0)  
 
3. How soon after you wake up do you smoke your first cigarette?  
a. Within the first 30 minutes (1)  
b. More than 30 minutes after waking but before noon (0)  
c. In the afternoon (0)  
d. In the evening (0)  
 
4. Which cigarette would you hate to give up?  
a. First cigarette in the morning (1)  
b. Any other cigarette before noon (0)  
c. Any other cigarette afternoon (0)  
d. Any other cigarette in the evening (0)  
 
5. Do you find it difficult to refrain from smoking in places where it is forbidden (church, 
library, movies, etc.)?  
a. Yes, very difficult (1)  
b. Yes, somewhat difficult (1)  
c. No, not usually difficult (0)  
d. No, not at all difficult (0)  
 
6. Do you smoke if you are so ill that you are in bed most of the day?  
a. Yes, always (1)  
b. Yes, quite often (1)  
c. No, not usually (0)  
d. No, never (0)  
 
7. Do you smoke more during the first 2 hours than during the rest of the day?  
a. Yes (1)  
b. No (1)  
 
  CONSENT FORM 
The Erode College Of Pharmacy   
 
PATIENT CONSENT FORM 
 
Participant written informed consent 
 I understand that my participation is voluntary and that I may withdraw from this study at 
any time without giving any reason or to decline to answer any particular question in the study. I 
consent the members of the study to have access to my response and to publish the result, 
provided my identity is not revealed. I voluntarily agree to participate in the study. 
 
 
 
               Participant signature with date 
 
